Skip to main content

Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations

  • Conference paper
Immunosurveillance, Immunodeficiencies and Lymphoproliferations

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 159))

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferations may arise in individuals with hereditary or acquired immunodeficiencies. T-cell dysfunction and resulting insufficient control of EBV infection is common to all these patients in whom EBV-associated lymphoproliferations develop. EBV is an oncogenic virus which induces proliferation and transformation of B-lymphocytes. Antiviral treatment may represent a causal treatment option with relatively low toxicity. Among the different antiviral drugs aciclovir and ganciclovir are not the drugs of choice, because in EBV-associated lymphoproliferations the viral thymidine kinase enzyme is not encoded regularly. The agent arginine butyrate has the ability to selectively activate EBV thymidine kinase genes in EBV-infected lymphoma cells. In combination with ganciclovir it has demonstrated efficacy in patients with EBV-associated lymphoproliferations after solid organ transplantation. The action of foscarnet, another antiviral agent, is directed against the viral DNA, independent of the presence of the viral thymidine kinase. In our experience treatment with foscarnet resulted in continuous complete remissions in patients with EBV-associated lymphoproliferations. These clinical experiences demonstrate the efficacy of antiviral treatment in EBV-associated lymphoproliferations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Henle G, Henle W (1979) The virus as the etiologic agent of infectious mononucleosis. In: Epstein MA, Achong BG (eds) The Epstein-Barr virus. Springer, Berlin Heidelberg New York, pp 297–320

    Chapter  Google Scholar 

  2. Klein G (1979) Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci USA 76:2442–2446

    Article  PubMed  CAS  Google Scholar 

  3. Klein G (1979) The relationship of the virus to nasopharyngeal carcinoma. In: Epstein MA, Achong BG (eds) The Epstein-Barr virus. Springer, Berlin Heidelberg New York, pp 339–350

    Chapter  Google Scholar 

  4. Starzl TE, Nalesnik MA, Porter KA et al. (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 11:583–587

    Article  Google Scholar 

  5. Littler E, Zeuthen J, McBride AA et al. (1986) Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J 5:1959–1966

    PubMed  CAS  Google Scholar 

  6. Mentzer SJ, Fingerroth J, Reilly JJ et aL (1998) Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr virus-associated lymphoma. Blood Cell Mol Dis 30:114–123

    Article  Google Scholar 

  7. Öberg B (1989) Antiviral effects of phosphonoformate. Pharmac Ther 2:213

    Article  Google Scholar 

  8. Hanto DW, Frizzera G, Gajl-Peczalska KJ et al. (1982) Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N Engl J Med 306:913–918

    Article  PubMed  CAS  Google Scholar 

  9. Hanto DW, Frizzera G, Gajl-Peczalska KJ et al (1985) Acyclovir therapy of Epstein-Barr virus-induced posttransplant lymphoproliferative diseases. Transplant Proc 17:89–92

    Google Scholar 

  10. Pirsch JD, Stratta RJ Sollinger HW et al. (1989) Treatment of severe Epstein-Barr virus-induced lymphproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 86:241–244

    Article  PubMed  CAS  Google Scholar 

  11. Swinnen L, Mullen GM, Carr TJ et al. (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86:3333–3340

    PubMed  CAS  Google Scholar 

  12. Mozzanica N, Cattaneo A, Fracchiolla N et al. (1997) Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction of immunosuppression. J Heart Lung Transplant 9:964–968

    Google Scholar 

  13. Oertel SH, Krause D, Ruhnke M et al. (1998) A standardized approach for treatment of post-transplant lymphoproliferative disease after solid organ transplantation. Blood 10(Suppl 1):239b

    Google Scholar 

  14. Faller DV, Hermine O, Small T et al. (2000) Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus associated lymphomas. Blood 11:577

    Google Scholar 

  15. Oertel SHK, Ruhnke MS, Anagnostopoulos I et al. (1999) Treatment of EBVinduced PT-LPD with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 15:765–767

    Article  Google Scholar 

  16. Schmidt W, Anagnostopoulos I, Scherubl H (2000) Virostatic therapy for advanced lymphoprolife rat ion associated with the Epstein-Barr virus in an HIV-infected patient. N Engl J Med 342:440–441

    Article  PubMed  CAS  Google Scholar 

  17. Schneider U, Ruhnke M, DelecJuse HJ et al. (2000) Regression of Epstein-Barr virus associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. Ann Hematol 79:214–216

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Oertel, S.H., Riess, H. (2002). Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56352-2_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62676-0

  • Online ISBN: 978-3-642-56352-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics